Redox regulation of DUBs and its therapeutic implications in cancer

Reactive oxygen species (ROS) act as a double-edged sword in cancer, where low levels of ROS are beneficial but excessive accumulation leads to cancer progression. Elevated levels of ROS in cancer are counteracted by the antioxidant defense system. An imbalance between ROS generation and the antioxi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Apoorvi Tyagi, Saba Haq, Suresh Ramakrishna
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Anticancer drugs Antioxidants Ubiquitin proteasome system Superoxide Therapeutics Medicine (General) R5-920 Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/9e86097e17c44e0584804c8b9f893765
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e86097e17c44e0584804c8b9f893765
record_format	dspace
spelling	oai:doaj.org-article:9e86097e17c44e0584804c8b9f8937652021-11-22T04:25:04ZRedox regulation of DUBs and its therapeutic implications in cancer2213-231710.1016/j.redox.2021.102194https://doaj.org/article/9e86097e17c44e0584804c8b9f8937652021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2213231721003542https://doaj.org/toc/2213-2317Reactive oxygen species (ROS) act as a double-edged sword in cancer, where low levels of ROS are beneficial but excessive accumulation leads to cancer progression. Elevated levels of ROS in cancer are counteracted by the antioxidant defense system. An imbalance between ROS generation and the antioxidant system alters gene expression and cellular signaling, leading to cancer progression or death. Post-translational modifications, such as ubiquitination, phosphorylation, and SUMOylation, play a critical role in the maintenance of ROS homeostasis by controlling ROS production and clearance. Recent evidence suggests that deubiquitinating enzymes (DUBs)-mediated ubiquitin removal from substrates is regulated by ROS. ROS-mediated oxidation of the catalytic cysteine (Cys) of DUBs, leading to their reversible inactivation, has emerged as a key mechanism regulating DUB-controlled cellular events. A better understanding of the mechanism by which DUBs are susceptible to ROS and exploring the ways to utilize ROS to pharmacologically modulate DUB-mediated signaling pathways might provide new insight for anticancer therapeutics. This review assesses the recent findings regarding ROS-mediated signaling in cancers, emphasizes DUB regulation by oxidation, highlights the relevant recent findings, and proposes directions of future research based on the ROS-induced modifications of DUB activity.Apoorvi TyagiSaba HaqSuresh RamakrishnaElsevierarticleAnticancer drugsAntioxidantsUbiquitin proteasome systemSuperoxideTherapeuticsMedicine (General)R5-920Biology (General)QH301-705.5ENRedox Biology, Vol 48, Iss , Pp 102194- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Anticancer drugs Antioxidants Ubiquitin proteasome system Superoxide Therapeutics Medicine (General) R5-920 Biology (General) QH301-705.5
spellingShingle	Anticancer drugs Antioxidants Ubiquitin proteasome system Superoxide Therapeutics Medicine (General) R5-920 Biology (General) QH301-705.5 Apoorvi Tyagi Saba Haq Suresh Ramakrishna Redox regulation of DUBs and its therapeutic implications in cancer
description	Reactive oxygen species (ROS) act as a double-edged sword in cancer, where low levels of ROS are beneficial but excessive accumulation leads to cancer progression. Elevated levels of ROS in cancer are counteracted by the antioxidant defense system. An imbalance between ROS generation and the antioxidant system alters gene expression and cellular signaling, leading to cancer progression or death. Post-translational modifications, such as ubiquitination, phosphorylation, and SUMOylation, play a critical role in the maintenance of ROS homeostasis by controlling ROS production and clearance. Recent evidence suggests that deubiquitinating enzymes (DUBs)-mediated ubiquitin removal from substrates is regulated by ROS. ROS-mediated oxidation of the catalytic cysteine (Cys) of DUBs, leading to their reversible inactivation, has emerged as a key mechanism regulating DUB-controlled cellular events. A better understanding of the mechanism by which DUBs are susceptible to ROS and exploring the ways to utilize ROS to pharmacologically modulate DUB-mediated signaling pathways might provide new insight for anticancer therapeutics. This review assesses the recent findings regarding ROS-mediated signaling in cancers, emphasizes DUB regulation by oxidation, highlights the relevant recent findings, and proposes directions of future research based on the ROS-induced modifications of DUB activity.
format	article
author	Apoorvi Tyagi Saba Haq Suresh Ramakrishna
author_facet	Apoorvi Tyagi Saba Haq Suresh Ramakrishna
author_sort	Apoorvi Tyagi
title	Redox regulation of DUBs and its therapeutic implications in cancer
title_short	Redox regulation of DUBs and its therapeutic implications in cancer
title_full	Redox regulation of DUBs and its therapeutic implications in cancer
title_fullStr	Redox regulation of DUBs and its therapeutic implications in cancer
title_full_unstemmed	Redox regulation of DUBs and its therapeutic implications in cancer
title_sort	redox regulation of dubs and its therapeutic implications in cancer
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/9e86097e17c44e0584804c8b9f893765
work_keys_str_mv	AT apoorvityagi redoxregulationofdubsanditstherapeuticimplicationsincancer AT sabahaq redoxregulationofdubsanditstherapeuticimplicationsincancer AT sureshramakrishna redoxregulationofdubsanditstherapeuticimplicationsincancer
_version_	1718418239553273856

Redox regulation of DUBs and its therapeutic implications in cancer

Ejemplares similares